TY - JOUR
T1 - Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis
T2 - baseline results of the MUSIC-OS study
AU - Modi, A.
AU - Sen, S.
AU - Adachi, J. D.
AU - Adami, S.
AU - Cortet, B.
AU - Cooper, A. L.
AU - Geusens, P.
AU - Mellström, Dan
AU - Weaver, J.
AU - van den Bergh, J. P.
AU - Nguyen, A. M.
AU - Sajjan, S.
AU - Adachi, Jonathan
AU - Khan, Aliya
AU - Schweitzer, Bradley
AU - Saunders, Kevin
AU - Du Preez, Miranda
AU - Bayly, Kenneth
AU - Lichtenstein, Tersia
AU - Boroditsky, Richard
AU - Corey, John S.
AU - Sinha, Jay
AU - Kooy, Jack
AU - Nayar, Arun
AU - Arndt, Suzanne
AU - Mohamed, Iman
AU - Olszynski, Wojciech P.
AU - Legroux, Isabelle
AU - Guinamand, Sandrine Malochet
AU - De Vernejoul, Marie Christine
AU - Roux, Christian
AU - Thomas, Eric
AU - Lévy-Weil, Florence
AU - Ursu, Corina
AU - Cortet, Bernard
AU - Barucq, Francois
AU - Bisch, Olivier
AU - Bouche, Philippe
AU - Breton, Nicolas
AU - Lacoin, François
AU - Makridis, Georgios
AU - Marmor, Philippe
AU - Ruetsch, Marcel
AU - Taminau, Denis
AU - Bismuth, Michel
AU - Bourgoin, Michel
AU - Sacareau, Didier
AU - Scellier, Christian
AU - Wurtz, Jean Louis
AU - Le Mouel, Stephane
AU - MUSIC-OS Study Group
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Summary: The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. Introduction: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. Methods: Baseline results are reported here for a prospective study which enrolled postmenopausal, osteoporotic women who were initiating (new users) or continuing (experienced users) osteoporosis treatment at study entry (baseline). A patient survey was administered at baseline and included the occurrence of GI symptoms during 6-month pre-enrolment, treatment adherence (adherence evaluation of osteoporosis (ADEOS), score 0–22), treatment satisfaction (Osteoporosis Treatment Satisfaction Questionnaire for Medications (OPSAT-Q), score 0–100) and HRQoL (EuroQol-5 dimension (EQ-5D) utility, score 0–1; OPAQ-SV, score 0–100). The association between GI symptoms and ADEOS (experienced users), OPSAT-Q (experienced users), and HRQoL (new and experienced users) was assessed by general linear models adjusted for patient characteristics. Results: A total of 2959 patients (2275 experienced and 684 new users) were included. Overall, 68.1 % of patients experienced GI symptoms in the past 6 months. Compared with patients without GI symptoms, patients with GI symptoms had lower mean baseline scores on most measures. The mean adjusted differences were ADEOS, −0.43; OPSAT-Q, −5.68; EQ-5D, −0.04 (new users) and −0.06 (experienced users), all P < 0.01. GI symptoms were also associated with lower OPAQ-SV domain scores: physical function, −4.17 (experienced users); emotional status, −4.28 (new users) and −5.68 (experienced users); back pain, −5.82 (new users) and −11.33 (experienced users), all P < 0.01. Conclusions: Patients with GI symptoms have lower treatment adherence and treatment satisfaction and worse HRQoL than patients without GI symptoms.
AB - Summary: The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. Introduction: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. Methods: Baseline results are reported here for a prospective study which enrolled postmenopausal, osteoporotic women who were initiating (new users) or continuing (experienced users) osteoporosis treatment at study entry (baseline). A patient survey was administered at baseline and included the occurrence of GI symptoms during 6-month pre-enrolment, treatment adherence (adherence evaluation of osteoporosis (ADEOS), score 0–22), treatment satisfaction (Osteoporosis Treatment Satisfaction Questionnaire for Medications (OPSAT-Q), score 0–100) and HRQoL (EuroQol-5 dimension (EQ-5D) utility, score 0–1; OPAQ-SV, score 0–100). The association between GI symptoms and ADEOS (experienced users), OPSAT-Q (experienced users), and HRQoL (new and experienced users) was assessed by general linear models adjusted for patient characteristics. Results: A total of 2959 patients (2275 experienced and 684 new users) were included. Overall, 68.1 % of patients experienced GI symptoms in the past 6 months. Compared with patients without GI symptoms, patients with GI symptoms had lower mean baseline scores on most measures. The mean adjusted differences were ADEOS, −0.43; OPSAT-Q, −5.68; EQ-5D, −0.04 (new users) and −0.06 (experienced users), all P < 0.01. GI symptoms were also associated with lower OPAQ-SV domain scores: physical function, −4.17 (experienced users); emotional status, −4.28 (new users) and −5.68 (experienced users); back pain, −5.82 (new users) and −11.33 (experienced users), all P < 0.01. Conclusions: Patients with GI symptoms have lower treatment adherence and treatment satisfaction and worse HRQoL than patients without GI symptoms.
KW - Bisphosphonates
KW - Gastrointestinal
KW - Health-related quality of life
KW - Osteoporosis
KW - Postmenopausal
KW - Treatment satisfaction
UR - http://www.scopus.com/inward/record.url?scp=84959180057&partnerID=8YFLogxK
U2 - 10.1007/s00198-015-3388-3
DO - 10.1007/s00198-015-3388-3
M3 - Article
C2 - 26637321
AN - SCOPUS:84959180057
SN - 0937-941X
VL - 27
SP - 1227
EP - 1238
JO - Osteoporosis International
JF - Osteoporosis International
IS - 3
ER -